Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Taps Cartagenia to Provide Microarray Data Analysis Software


Cartagenia said this week that CombiMatrix, an Irvine, Calif.-based molecular diagnostics firm, has selected its Bench lab software for copy number variant analysis.

CombiMatrix will use the software to handle microarray data analysis, interpretation, and reporting for its postnatal and prenatal testing service.

Cartagenia said that it will tailor the software to CombiMatrix's variant assessment and reporting workflow so that the company can perform interpretation and reporting without having to disrupt its established operating procedures. Additionally, Cartagenia will also integrate the software with existing information technology systems at CombiMatrix.

Richard Hockett, CombiMatrix’s chief medical officer, explained that the company selected Cartagenia’s software because the company “clearly positions its solutions for clinical use," which is "in contrast to other software packages.”

Furthermore, "with our lab operations and test volumes growing, it made perfect sense to select the Cartagenia Bench platform at this time,” he said in a statement.

“We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more,” Hockett explained. “The automation provided by Bench lab CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing.”

In addition to CombiMatrix, Cartagenia’s client list includes Credit Valley Hospital lab, an Ontario-based clinical cytogenetic laboratory (BI 5/18/2012), as well as Gene DX and the Los Angeles Children’s Hospital (BI 3/23/2012).

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.